Press Releases

Title Company Date
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon – Novocure Novocure May 2024
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon Tarsus April 2024
Pharmakon Advisors provides $275 Million Debt Facility to Reata Pharmaceuticals Reata May 2023
BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon BioCryst April 2023
ImmunoGen signs loan agreement with Pharmakon for up to $125m ImmunoGen April 2023
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update Immunocore Immunocore November 2022
Insmed Announces Strategic Financings Totalling $775 Million Insmed 19 October 2022
UroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow Breakeven UroGen 8 March 2022
Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio Collegium 14 February 2022
Coherus BioSciences Secures Credit Financing with Pharmakon Advisors Coherus 7 January 2022
Evolus Enters Into $125 Million Credit Facility with Pharmakon Advisors Evolus 14 December 2021
LumiraDx, a Next-Generation Point of Care Diagnostics Testing Company to List on Nasdaq via Merger with CA Healthcare Acquisition Corp LumiraDx 23 March 2021
Collegium Announces Closing of the Nucynta Franchise Acquisition Collegium 13 February 2020
GBT Secures $150 Million Non-Dilutive Term Loan Financing GBT 18 December 2019
Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing Sarepta 13 December 2019
AKEBIA SECURES $100 MILLION NON-DILUTIVE TERM LOAN FINANCING; REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS Akebia 12 NOVEMBER 2019
EPIZYME ESTABLISHES AGREEMENTS FOR UP TO $270 MILLION IN FUNDING TO SUPPORT TAZEMETOSTAT COMMERCIALIZATION AMD PIPELINE ADVANCEMENT Epizyme 4 NOVEMBER 2019
Optinose Announces $150 Million Debt Financing from Pharmakon Optinose 12 September 2019
BioDelivery Sciences Strengthens Financial Position with Debt Refinancing BioDelivery Sciences 28 May 2019
Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders Amicus 20 September 2018
Novocure Secures New $150 Million Non-Dilutive Term Loan Financing Novocure 7 February 2018
LEXICON PHARMACEUTICALS SECURES UP TO $200 MILLION NON-DILUTIVE TERM LOAN FINANCING Lexicon 5 December 2017
TESARO Secures $500 Million Non-Dilutive Term Loan Financing Tesaro 21 November 2017
iRhythm Technologies iRhythm 7 August 2017
Depomed Announces Prepayment of $100 Million of Secured Debt Facility Depomed 4 April 2017
BioPharma Credit PLC US$ 762 million IPO and admission to trading on the London Stock Exchange, bringing total capital raised by Pharmakon funds to US$ 2.4 billion Merrimack 3 April 2017
Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors Novocure 1 July 2016
Halozyme Announces Closing Of $150 Million Royalty-Backed Debt Financing Halozyme 26 January 2016
Halozyme Enters Into Agreement For $150 Million Non-Dilutive Royalty-Backed Debt Financing Halozyme 4 January 2016
Depomed Secures $575 Million Debt Facility From Deerfield and Pharmakon to Finance the Closing of NUCYNTA® Acquisition Depomed 12 March 2015
Novocure Announces $100 Million Term Loan Agreement with Pharmakon Advisors Novocure 8 January 2015
Specialty Vaccine Company PaxVax Secures Up to $60 Million in Financing PaxVax 28 July 2014
Valneva Secures USD 30M New Financing and Confirms Sale of Clinical Manufacturing Operations in France Valneva 9 December 2013
Amarin announces $100 million non-equity financing and Vascepa sales force hiring while continuing to assess strategic alternatives Amarin 6 December 2012
Corcept Therapeutics Announces $30 Million Synthetic, Capped Royalty Transaction; Terminates Committed Equity Financing Facility Corcept 7 August 2012

Disclaimer

Copyright © 2018 Pharmakon Advisors, LP, All Rights Reserved.
Website Design By Alex Delmont Limited

 

The content of this website is provided by the Adviser and offers information about the Adviser and its affiliates and a general overview of its investment program. The content of this website is provided for information purposes only. Nothing on this website shall be construed as an offer to sell or a solicitation of an offer to purchase interests in any private fund managed by the Adviser, nor do they constitute investment advice. The information contained herein is subject to change without notice.

Offers and sales will be made only in accordance with applicable securities laws and pursuant to a confidential private placement memorandum (or similar document) and other fund governing documents, which should be read carefully and in their entirety prior to making an investment. Potential investors should not rely on any of the content of this website in making an investment or other decision but should obtain relevant and specific professional advice.

The content of this website and the investment program which might be referred to therein are not directed at, or intended for, distribution to any person or entity being a citizen or resident of, or located or established in, any jurisdiction where the use of such websites or the sale of such investment programs would be illegal or would require any registration or licensing not held by the Adviser. Such persons or entities access this website at their own risk and must observe any legal or regulatory restrictions which may affect their eligibility to access this website.  The Adviser makes no warranty or guarantee as to the accuracy, completeness or reliability of any information contained on this website. The Adviser shall have no liability for any direct, indirect, consequential or special losses or damages of any kind whatsoever arising from reliance on any of the content of this website.

I decline I understand and agree
Loading...